dx.doi.org/10.1056/NEJMoa250… leaving aside the data (...) 142250 people randomised in this massive trial. Only 13 authors. Is that everyone who made a substantial contribution, I wonder?
jw.org/en/global-communicati… quite big news for the transfusion community.
Bernard Maybury retweeted
I used to be a vocal skeptic of Hans and a key GEP fan, some say as an OG for GEP. I used to lament Hans IHC as the only tool available for my patients, when many trials used GEP instead.
But I have been surprised by learning how IHC has dramatically improved over the last decade or so with availability of standardized antibody clones, use of auto strainers, and interpretation consistency.
How was I convinced?
We did a systematic meta-analysis of >2200 patients from 19 studies. We used the PRISMA diagnostic test accuracy framework for comparing Hans to GEP.
library.ehaweb.org/eha/2026/…
Remarkably, this analysis now clearly shows that Hans is consistently non-inferior to GEP across current modern studies at a 10% NI margin for Accuracy, Precision, and Specificity.
This solid performance of Hans IHC is very much in line with current CAP benchmarks for diagnostic tests, and within the margins of NanoString GEP using FFPE vs original frozen GEP as the original elusive gold standard.
Long live Hans as the best currently available SOC for COO across the globe.
I'm bewildered we ever started giving pegfilgrastim at 24hrs. See some crazy early neutrophilias and disabling pain. We never gave regular GCSF this early
💉 Pegfilgrastim timing matters
📊 Phase III RCT (breast cancer)
⏱️ 72h vs 24–48h post-CT
📉 Bone pain (AUC): 6.05 vs 12.7–14.2 🔥
📉 Severe pain: 22.6% vs ~60%
⚖️ No ↑ neutropenia or FN
💡 Delaying to 72h may reduce toxicity without compromising efficacy
🔗 doi.org/10.7326/ANNALS-25-02…
@OncoAlert
Bernard Maybury retweeted
@houndcl was the first and major whistleblower for the Time-of-day @naturemedicine paper, which resulted in significant investigations across biomedical field and subsequent editorial actions for the paper
This had major impacts in saving research fundings and patient outcome. But in return @houndcl was banned from X
Can @elonmusk and @nikitabier please look into this?
And can big BioX & academic accounts please help retweeting for awareness too?
#freehoundcl
so our guy @houndcl of infamy has had his appeal denied. guilty of questioning research. #freehoundcl @nikitabier
Bernard Maybury retweeted
Very proud of our group today and especially Andrew Challenger's work looking at excess mortality in DLBCL patients- which persists even beyond 10 years from diagnosis. Needs to be considered in our trial designs! @DavidJCutter @graham74GC
doi.org/10.1182/bloodadvance…
Clinical Proof of concept for p53 reactivation in TP53 Y220C mutated cancers
nejm.org/doi/full/10.1056/NE…
Bernard Maybury retweeted
In 1999, Tom Maniatis discovered something remarkable: neurons achieve self-avoidance via stochastic methylation of the protocadherin gene cluster.
We've just discovered this locus is an evolvable in-vivo barcode across the human tissues: biorxiv.org/cgi/content/shor… 🧵
Bernard Maybury retweeted
access to an anti-CD20/CD3 bispecific in routine clinical care in the UK - finally following @NICEComms approval of epcoritimab #FL #lymsm
Impact of graft‐versus‐host disease prophylaxis strategies on GvHD‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis onlinelibrary.wiley.com/doi/…
Bernard Maybury retweeted
Tune in as Dr Charles Percy breaks down the new joint BSH–UKHCDO Guideline on acquired coagulation factor inhibitors.
A clear, practical conversation about what the 2025 guidance means for clinical practice.
bit.ly/45KnAbV
Great work by Dan Hodson's lab and colleagues demonstrating the utility and feasibility of ctDNA in LBCL, congratulations to all those involved!
Krupa et al - DIRECT study
• prospect live study ctDNA in LBCL
• phased variant, EoT with 24mo FU
• 2y time to tumour progn 42% (detected, D)v 95% (unD)
• better than PET
• Transfomed FL may give false +ve
Great work!
@CRUKCambridge
ascopubs.org/doi/10.1200/JCO…
Bernard Maybury retweeted
Delighted to share initial results of the CRUK ph I/II trial of aleta 001, a 1st in class CAR T engager protein at #ASH2025
✅ Excellent safety profile
✅ No DLTs
✅ No SAEs beyond gr1 CRS
✅ Robust and sustained CAR T expansions @BioAleta @PDRennert @immunologydoc @uhbtrust
Bernard Maybury retweeted
Fantastic talk today by Vaishali Dulobdas at #ASH2025 on effect of immune parameters and IgRT on post CD19 CAR T outcomes. #lymsm #uhbtrust #nickduncan31 @Capt__Kirkwood @immunologydoc @lymphomule @CCHBham @Paneeshas @lymphomahub @DrLindsayG
Bernard Maybury retweeted
Impact of IVIG on post-CAR survival #ASH25
- 430 pts, most LBCL & axicel
- low IgA at 1 & 3 mos = increased NRM at all timepoints
- low baseline IgM = worse PFS/OS
- 20% got IVIG: no effect on NRM!
No impact of IgG on survival! Provocative & supports selective use of IVIG. #lymsm
Bernard Maybury retweeted
Sorry but I fail to see how what price the NHS pays for drugs (prices that the companies agreed to), leads to reduced investment in UK by pharma. Total BS. The two are not linked. R&D is a global business, UK sales is small fry. – at Huntington, England
Bernard Maybury retweeted
I've been reporting in East Africa on the impact of President Trump's USAID cuts, and I find that not only are children dying in large numbers but the pace is accelerating as stockpiles run out and people grow weaker. I also obtained an internal Trump administration memo stating that the cost of shutting down USAID is $6.4 billion over two years. That sum could save more than 1 million children's lives; instead, it is being spent to to shut down programs that save lives. Help spread the word. nytimes.com/2025/09/20/opini…
Bernard Maybury retweeted
Medical Imaging and Pediatric and Adolescent Haem cancer Risk
During 35,715,325 person-yrs of f/up (mean, 10.1 yrs/person)
2961 Haem CA diag
primarily lymphoid CA: 79.3%
10.1% (95% CI, 5.8 to 14.2) of hem ca may have been attrib to radiation exposure from medical imaging
@NEJM
A retrospective cohort study involving children born between 1996 and 2016 suggests a significant but small associated increased risk of hematologic cancer among those exposed to radiation from medical imaging. Full study results: nej.md/41YXEHD
Editorial: Studying Cancer Risks Associated with Diagnostic Procedures — Interpret Wisely nej.md/3IqJ8Sf
ALT A graph showing the relative risk of hematologic cancer for a dose of 30 mGy (vs. no exposure), according to time since exposure and age at exposure.
Bernard Maybury retweeted
🎧 In our latest podcast, Prof. Christopher Fox, Dr. Sridhar Chaganti, and Dr. Bernard Maybury discuss the 2025 guideline on managing relapsed or refractory large B-cell lymphoma
b-s-h.org.uk/guidelines/guid…
ALT Close-up of a golden microphone and laptop used for audio editing.
I was going to tweet about this work at just published in @BrJHaem but @richardbuka got there first. A great 🧵
1/ Pleased to have been involved in this study in @BrJHaem that looks at secondary & idiopathic polycythaemia. This is not a fashionable area but a big deal that takes up a lot of time in the clinic. We looked at management and thrombosis rates in two large centres in England.
